Pomalidomide (Pomalyst) appears in one listed capsule product, Pomalyst. The Immunomodulatory imide drug classification provides context for the Oncology Support treatment area. Product details identify the specific presentation and ingredient composition, while the catalogue brings its stated strength and formulation together for comparison.
Multiple Myeloma in Combination with Bortezomib and Dexamethasone in Adult Patients Who Have Received At Least One Prior Treatment Regimen Including Lenalidomide
4mg
Treats relapsed and refractory multiple myeloma by modulating the immune system and directly targeting tumour cells through cereblon binding, producing anti-proliferative, anti-angiogenic and immunomodulatory effects.
Related medicines appear within Oncology Support.
Information about Pomalidomide on this page is an educational overview, not medical advice. Products can differ in formulation, strength, and directions, and this content does not authorise clinical application or unsupervised use. Review the labelling for each product and speak with a healthcare professional whenever clinical judgement is needed. Product-specific contraindications, interactions, and reactions should be checked in the product labelling and verified clinical sources.
